(Hypertension. 1997;30:259-266.)
© 1997 American Heart Association, Inc.
Articles |
From the Division of Nephrology, Hennepin County Medical Center (S.A.K., J.A.O., L.M.F.), Minneapolis, Minn; and the Departments of Physiology (S.A.K.) and Medicine (J.A.O., A.T.H.) and the Vascular Medicine Program, Minnesota Vascular Diseases Center (M.M.L., A.T.H.), University of Minnesota Medical School, Minneapolis.
Correspondence to Stephen A. Katz, Associate Professor of Physiology, University of Minnesota School of Medicine and Senior Investigator, Hennepin County Medical Center, Division of Nephrology, D Bldg, 5th Floor, 701 Park Ave, Minneapolis, Minnesota 55415-1829. E-mail katzx001{at}maroon.tc.umn.edu
| Abstract |
|---|
|
|
|---|
Key Words: renin myocardium renin glycoforms angiotensinogen renin-angiotensin system
| Introduction |
|---|
|
|
|---|
Therefore, the first purpose of this study was to assess myocardial and plasma renin and angiotensinogen concentrations under control and anephric conditions. BNX causes contrasting changes in plasma renin and plasma angiotensinogen concentrations, which should be mirrored within the myocardium if plasma is the major source of these myocardial components.
Active rat renin consists of five major glycoforms (I through V), which can be separated by high-resolution isoelectric focusing (renin glycoform profile). Plasma renin activity is equal to the sum of the activities of multiple circulating glycoforms. Renin glycoforms I and II possess high-mannose-type oligosaccharides and relatively small net negative charge.8 In addition, glycoforms I and II represent the predominant storage form of active renin in the kidney, are preferentially secreted by the kidney after acute stimulation, have relatively short plasma half-lives, and have very low vascular wall permeability compared with the other renin glycoforms.9 10 11 12 13 14
Thus, the second purpose of this study was to examine the hypothesis that active renin charge or oligosaccharide heterogeneity might confer a preferential distribution of specific renin glycoforms within the myocardium. Nephrectomy intervention provides an experimental opportunity to assess whether plasma is the major source of myocardial renin glycoforms and whether the myocardial permeability of renin glycoforms I and II is low compared with other renin glycoforms.
| Methods |
|---|
|
|
|---|
Sample Preparation
Approximately 7 mL of trunk blood was collected into tubes
containing 200 µL of 5% EDTA. The blood was mixed, stored on ice,
and centrifuged at 2000g for 15 minutes at 4°C.
Separated plasma was snap frozen in liquid N2 and stored at
-25°C for subsequent determination of plasma active renin,
angiotensinogen, and renin glycoforms. Hearts were quickly
excised, followed by retrograde perfusion of the aorta with 10 mL
ice-cold heparinized saline and removal of pericardial tissue, atria,
great vessels, and right ventricle. Both sides of the left
ventricular wall were then blotted, weighed, snap frozen in
liquid N2, and stored at -25°C. Total left ventricle
preparation time was approximately 3 minutes.
Left ventricles were homogenized at 0°C in a hand-held 7-mL Kontes glass homogenizer at a ratio of 1 mg tissue to 5 µL PIB containing serine-, metallo-, and thiol-protease inhibitors and 0.15 mol/L sodium phosphate buffer (pH 7.5) containing EDTA (15 mmol/L), 8-hydroxyquinoline (2 mmol/L), sodium tetrathionate (10 mmol/L), benzamidine (20 mmol/L), N-ethylmaleimide (10 mmol/L), AEBSF hydrochloride (PEFABLOC, 1 mmol/L), leupeptin (10 µmol/L), aprotinin (450 µmol/L), and 1.0% BSA. Homogenates were split into three aliquots and stored at -25°C. Each set of three myocardial aliquots was thawed and centrifuged at 14 000g for 4 minutes at 4°C, and the supernatants were assayed for active renin, active renin glycoforms, or angiotensinogen.
Plasma and Myocardial Renin Measurement
Plasma was diluted between 7-fold and 30-fold in PIB to yield
renin concentrations similar to myocardial homogenates,
lesser dilutions being required for BNX plasma samples. Both plasma and
homogenates were therefore diluted in the same solvent
(PIB) and assayed identically as follows. Duplicate assay tubes
contained 80 µL of diluted plasma, myocardial homogenate,
or PIB (sample blanks), which was combined with 150 µL additional PIB
and 75 µL 48-hour BNX unfractionated rat plasma
(angiotensinogen source). In general, PIB
represented at least 70% of the assay volume, so that all
proteolytic inhibitors were well above their effective
working minimum concentration. Two 100-µL aliquots were incubated at
0°C and another two 100-µL aliquots incubated at 37°C, both for
18 to 24 hours. Detectable average Ang I in the 0°C tubes
(endogenous immunoreactive Ang I in sample and substrate
source) was subtracted from the 37°C tube average to calculate
generated Ang I, although the 0°C-tube Ang I concentrations were
often undetectable in relatively high renin plasma and corresponding
myocardial homogenate samples (see below for corresponding
isoelectric focusing background subtraction). The corresponding
difference in the sample blank tubes was also subtracted from the
generated Ang I value to correct for endogenous renin
activity in the substrate source. Sample blanks ranged from 3% to 30%
of the generated Ang I, with the exception of the 48-hour BNX plasma
samples, whose sample blank was nearly 75% of the generated Ang I.
During the 37°C incubation, Ang I was generated in direct proportion
to the sample renin concentration. Only 4% or less of the total
available angiotensinogen was converted to Ang I, and
linear generation of Ang I over time was verified throughout the
study.15 16 Renin concentration was expressed as nanograms
Ang I per milliliter plasma or gram myocardium per hour
incubation.
Ang I was assayed by RIA, using a modified DuPont Ang I RIA kit. Major modifications included preparation of Ang I standards with the same solution contents as samples. RIA assay data were linearized with a log-logit transformation, resulting in a correlation coefficient of -.99 or better. The average labeled Ang I bound 60% to the primary antibody without competition. The average percent of error for predicting the standard concentration from the transformed curve was less than 6%. Ang I recovery from spiked samples was a function of the absolute Ang I concentration. In general, recoveries were between 94% and 106% at Ang I concentrations between 0.1 and 5 ng/mL, but above 5 ng/mL, recovery steadily decreased. As a result, all assays were kept between 0.1 and 5.0 ng Ang I per milliliter.
Angiotensinogen Measurement
Angiotensinogen concentrations from left
ventricular myocardial homogenate supernatants
and plasma were measured by adding a large excess of exogenous porcine
renin and subsequently converting all sample
angiotensinogen to Ang I (verified by Ang I generation
plateau). Ang I concentrations were then determined by RIA, and
corresponding angiotensinogen concentrations were
calculated on the basis of a 1:1 molar relationship between Ang I
generation and angiotensinogen depletion. Plasma was
diluted 70-fold in PIB to yield comparable angiotensinogen
concentrations to myocardial homogenates. Both plasma and
homogenates were therefore diluted in the same solvent
(PIB) and assayed identically as follows. Porcine renin (7 mU, Sigma
Chemical Company) in 325 µL PIB was added to 25 µL diluted plasma
or myocardial homogenate at 0°C and then incubated in
duplicate at 37°C for 20 minutes. Another set of duplicates was
incubated for 40 minutes. Care was taken to ensure that samples were
not warmed before the incubation step. Appropriate combinations of
porcine renin and PIB, plasma and PIB, homogenates and PIB,
or PIB alone yielded no detectable Ang I. The average percent
difference between the Ang I concentration determined from the 20- and
40-minute time points was -0.36% and -4.04% for plasma and
myocardial homogenates, respectively, indicating that an
Ang I generation plateau had been reached by 20 minutes and that Ang I
is relatively stable in the assay. The assay was repeated in selected
samples with 2 mU or 70 mU of renin addition, and resulting
angiotensinogen determinations at 20 and 40 minutes'
incubation were within 9.3% of the 7-mU renin addition, indicating
that excess renin was being employed in the angiotensinogen
assay. Furthermore, spiking ventricular
homogenates with plasma yielded predictable
angiotensinogen determinations equal to the sum of the
homogenate plus plasma values determined separately.
Addition of enalaprilat to the PIB yielded no differences in the amount
of angiotensinogen measured. The minimal myocardial
angiotensinogen detection limit was approximately equal to
15% of the control myocardial angiotensinogen values.
Shallow-Gradient Isoelectric Focusing
Rat active renin was resolved into five major glycoforms (I
through V) by using shallow-gradient isoelectric
focusing.8 Plasma (600 µL) was incubated with 15 mg
SiO2 at 20°C for 30 minutes followed by
centrifugation at 100 000g at 4°C for 30
minutes. Aliquots (100 to 200 µL) of the plasma supernatants were
applied to the focusing gels. Ventricular
homogenate (1200 µL) was incubated with 30 mg
SiO2 at 20°C for 30 minutes followed by
centrifugation at 100 000g at 4°C for 30
minutes. The homogenate supernatant was concentrated
fivefold by dialysis (4000 to 6000 molecular weight cutoff) against
solid polyethylene glycol (molecular weight 15 000 to 20 000) and
again centrifuged at 100 000g at 4°C for 30
minutes. Samples (200 µL) of the homogenate supernatants
were applied to focusing gels. Focusing was carried out as described
previously.8 14
After the run, each gel was frozen and serially sliced into approximately 60 gel segments. Each gel segment was eluted in an individual polystyrene tube with 125 µL PIB at 4°C. Gel segments initially swelled and then reached diffusion equilibrium approximately 18 to 24 hours later. The gel segments were then carefully removed, leaving behind approximately 90 µL of eluant (with renin present, if the enzyme had focused in the corresponding gel segment).
Renin Glycoform Measurement
Each 90 µL of eluant was then combined with 30 µL of plasma
from 48-hour bilaterally nephrectomized rats as an
angiotensinogen source. The total 120 µL was then
incubated at 37°C for 1 to 24 hours; longer incubation times were
necessary for samples with relatively little renin activity. The Ang I
generated in the entire 120-µL incubation mixture (assay tube) was
then measured by RIA. Yields for this system are very close to 100%,
assuming diffusion equilibrium between gel slice and
eluant.8 16 Figures showing the resulting renin glycoforms
separated by isoelectric focusing are raw data expressed as nanograms
Ang I per total incubation time per milliliter assay tube.
Determination of Renin Glycoform Proportions
Zero time Ang I immunoreactivity and residual renin activity in
the substrate represent background error subtracted from all
gel segments containing renin activity to calculate glycoform
proportions. This background error correction was determined from gel
slices that clearly contained no sample renin activity due to their
correspondingly high or low isoelectric points. The background error is
equivalent to the sample blanks for the plasma and myocardial renin
assays. Subtraction of background and calculation of the five major
renin glycoform proportions resolved in the gels was performed as
previously reported.8 16 Briefly, the amount of net renin
activity (after background subtraction) in each of the five renin
activity peaks (renin forms I throughV) was measured by summing the
renin activity in each gel segment corresponding to an individual renin
activity peak. Identification of each gel peak as a specific renin form
was accomplished by identification of the corresponding isoelectric
point of the gel segment from identical gels run in parallel and
verification by observation of the relative position of a peak in
relation to other peaks in the gel.
Focusing gel renin activity was then calculated by expressing the amount of renin activity (nanograms Ang I generated per total incubation time per milliliter assay tube) in each of five glycoform peaks as a percent of the total net renin activity recovered from the focusing gel. The activity of each of the five renin glycoforms was then expressed as a proportion (percentage) of the total net renin activity recovered from the gel.
Statistical Analysis
Comparisons between plasma and myocardial concentrations of
active renin and angiotensinogen and between low-salt and
normal-salt rats were performed by using unpaired Student's
t tests. Renin glycoform comparisons were made by summing
the proportions of the two least negatively charged renin glycoforms
(highest isoelectric points, renin glycoforms I and II) and comparing
the sum of renin glycoform proportions I+II in plasma and
myocardium before and after BNX. Combining renin glycoform
I and II proportions allowed assessment of statistical differences
without reference to specific renin forms that are a function of the
isoelectric pH gradient12 and also allowed direct
analysis of the glycoforms that are known to participate in
acute plasma concentration changes after stimulation or inhibition of
renin secretion. Differences in proportions of renin forms were
assessed by Student's t test after arcsine transformation
of proportions to equalize variances between groups. Statistical
significance was assumed at P
.05 (two-tailed).
| Results |
|---|
|
|
|---|
|
Control myocardial homogenates were prepared from a separate set of five low-salt rats and assayed as described above and also after an additional centrifugation at 100 000g for 1 hour at 4°C to pellet all myocardial membranes. This latter high-speed centrifugation resulted in pelleting of 12±3.8% of homogenate renin. However, after washing the pellet in PIB and again centrifuging at 100 000g for 1 hour at 4°C, all original pellet renin activity was present in the supernatant and none could be measured in the recentrifuged pellet with or without the presence of 1% Triton X-100.
Under control conditions, plasma angiotensinogen was
1.5±0.04 µmol/L, while the corresponding myocardial
angiotensinogen concentration was only 0.042±0.004
µmol/kg myocardium (Fig 2
). Approximately 2 minutes after BNX and
with the animals still under pentobarbital anesthesia,
plasma and myocardial angiotensinogen concentrations were
not different (Fig 2
, 0 hours) from control values. Subsequent plasma
and myocardial angiotensinogen measurements at 6 and 48
hours post-BNX revealed that both plasma and myocardial
angiotensinogen concentrations increased. Compared with
control concentrations, 48-hour BNX plasma and myocardial
angiotensinogen levels increased approximately 4-fold and
12-fold, to 5.5±0.2 µmol/L plasma and 0.49±0.08
µmol/kg myocardium, respectively. Both increases
were statistically significant (P<.0002).
|
Assuming all myocardial renin and angiotensinogen measured in this study was confined to an interstitial space of 20 mL/100 g of left ventricle with a density of 1 mL/g (see "Discussion"), the myocardial interstitial Ang I generation rate derived from the control renin and angiotensinogen myocardial concentrations and in vitro incubation was 2.9 ng Ang I per milliliter interstitial space per hour. The corresponding control plasma Ang I generation rate was 16.0 ng Ang I per plasma per hour.
Control myocardial renin was 24.1±2% of plasma renin. This
distribution percentage was not significantly different from
experiments done with rats fed a normal (0.4% sodium)-salt diet
(Table
). Control myocardial
angiotensinogen was 2.7±0.25% of plasma
angiotensinogen values and was significantly different from
normal-salt rats, although both angiotensinogen
distribution percentages were quite low relative to the distribution
percentages for renin (Table
).
|
Five major active renin glycoforms were found in both plasma and the
myocardium (renin glycoforms I through V, with
corresponding average isoelectric points of 5.7, 5.4, 5.2, 5.0, and
4.8; Fig 3
). Under control conditions,
renin glycoforms I+II represented 45.2±3.0% of plasma
renin and 49.9±4.2% of myocardial renin and were not significantly
different (Figs 3
and 4
). In additional
experiments with normal (0.4% sodium)-salt rats (Table
), plasma
glycoform proportions I+II were 49.7±0.91% (n=4) and were not
significantly different from the low-salt rats. Corresponding
normal-salt myocardial renin glycoform proportions I+II were
47.4±3.51% (n=4) and were not significantly different from low-salt
rats. Normal-salt rats did display significantly lower plasma renin and
angiotensinogen concentrations, as well as a lower
myocardial renin concentration (Table
).
|
|
Six hours after BNX, the proportions of plasma active renin glycoforms
I+II fell significantly to 24.7±2.7% (Fig 4
), consistent with
preferential hepatic extraction of these circulating glycoforms, as
reported previously. However, the proportions of active renin
glycoforms I+II in the myocardium had increased
significantly to 62.6±3.2% of active renin 6 hours after BNX (Figs 4
and 5
), during a time when the
concentration of active renin in the myocardium was
decaying and the proportions of circulating glycoforms I+II were
decreasing significantly. The absolute levels of glycoforms I+II
(nanograms Ang I generated per total incubation time per milliliter
assay tube) in control and BNX plasma were 34.1±5.0 and 11.6±3.8,
respectively. The absolute levels of glycoforms I+II (nanograms Ang I
generated per total incubation time per milliliter assay tube) in
control and BNX myocardium were 9.0±1.4 and 7.5±1.0,
respectively. Myocardial glycoforms III, IV, and V were barely detected
6 hours after BNX (Fig 5
).
|
| Discussion |
|---|
|
|
|---|
The myocardial renin measured in this study was apparently not membrane bound. Although 12±3.8% of the myocardial homogenate renin was ultracentrifuged and pelleted with cardiac membranes, this renin activity could be separated from the membrane fraction with a single wash step, indicating nonspecific pelleting of renin along with cardiac membranes in the first ultracentifugation run. A previous study3 also observed about 12% of the myocardial renin associated with the cardiac membrane fraction, but in that study, the renin activity consistently stayed with the membrane fraction after washing. It is possible that renin binding was not demonstrable in the present study due to differences in animal species, degree of renin stimulation, or buffer systems used in the preparation of the myocardial homogenates.
Forty-eight hours after BNX, plasma and myocardial renin concentrations fell 95% and 85%, respectively, suggesting that most myocardial renin is derived from plasma renin of renal origin. Myocardial renin at 48 hours BNX was still above the lower level of detection for all animals studied (significantly above sample blanks). The low myocardial renin concentration at 48 hours BNX may have been due to slow myocardial renin diffusion into the plasma compartment secondary to hepatic clearance of plasma renin, as well as preferential myocardial trapping of renin glycoforms I+II, as discussed below. In addition, the possibility that myocardial renin synthesis is responsible for the 15% of myocardial renin remaining at 48 hours BNX cannot be excluded. Although controversial,2 myocardial gene expression for all constituents of the RAS have been demonstrated,20 and myocardial renin gene expression has been reported to increase secondary to volume overload (cardiac stretch).21 It should also be noted that in normal-salt animals, renin concentration after BNX decayed to levels that were close to the lower limits of detection. Therefore, we used chronic low-salt rats. It may be that a low-salt diet altered the percentage of myocardial renin seen after 48 hours BNX (15% of low-salt controls).
After BNX and careful attention to cathepsin D inhibition, Fordis et al22 were unable to measure renin activity in rat aorta and microvessels. In addition, Schwieler et al23 were unable to demonstrate local de novo synthesis of Ang II in gracilis muscle vasculature. In this report, control myocardial renin per gram tissue was much higher than previous vascular reports14 and much higher after 48 hours BNX than comparable vascular BNX studies.14 22 This may be due to a larger myocardial versus vascular interstitial space14 or myocardial synthesis of renin.
This study attempted to rule out two potential artifacts that may have been present in previous studies. The first artifact is the possible measurement of myocardial reninlike activity not due to renin. In the present study, this possibility appears unlikely for four reasons: (1) Unfractionated BNX plasma was used as an angiotensinogen source at pH 7.5 during Ang I generation, conditions which inhibit cathepsin D activity.2 In our assay, cathepsin D activity is over 97% inhibited when assayed at pH 7.5 versus pH 4.5. (2) The isoelectric focusing profile of myocardial renin activity matched the focusing profile of plasma renin and did not match the focusing profile of rat cathepsin D (rat cathepsin D isoelectric points range from 6.0 to 6.2 in a focusing system that focuses rat renin between 5.35 and 5.6524 ). (3) A combination of serine-, metallo-, and thiol-protease inhibitors was employed during Ang I generation, preventing interference by many other nonspecific proteases. (4) Myocardial renin activity fell after BNX, an unlikely result for a nonrenin myocardial enzyme.
The second potential artifact concerns contamination of myocardial homogenates by plasma-derived renin or angiotensinogen. In this study, plasma contamination was minimized by retrograde perfusion of the aorta with 10 mL ice-cold heparinized saline and blotting both sides of the left ventricular wall before freezing and assay. The fact that plasma and myocardial renin glycoform proportions were significantly different after 6 hours BNX also indicates that plasma renin contamination of myocardial homogenates was probably not significant.
If myocardial angiotensinogen was confined to the interstitial space, its concentration would be expected to be approximately 18% to 25% that of plasma, assuming simple diffusion equilibrium between plasma and myocardial interstitial fluid. In this study, the ratio of control myocardial to plasma angiotensinogen was only 2.7±0.25%. Therefore, in control animals, cardiac angiotensinogen concentration was lower than predicted on the basis of diffusional equilibrium.
In vivo enzymatic cleavage of angiotensinogen by renin in the myocardium probably contributed to the low control myocardial angiotensinogen levels measured in this study. Both plasma and myocardial angiotensinogen increased after BNX, but myocardial angiotensinogen increased more. Presumably, the disproportionate increase in myocardial angiotensinogen was secondary to both elevated levels of plasma angiotensinogen entering the myocardial interstitium after BNX and less available myocardial renin, causing less enzymatic destruction of angiotensinogen after BNX. At 48 hours BNX, the myocardial concentration of angiotensinogen relative to plasma was significantly elevated above the control value of 2.7±0.25% and equaled 8.9±1.5% of plasma angiotensinogen. After 48 hours BNX, myocardial angiotensinogen distribution was somewhat similar to myocardial albumin. Albumin has similar charge and mass to angiotensinogen and undergoes no myocardial enzymatic breakdown. Previous measurements of myocardial albumin distribution have ranged from 6% to 16% of plasma and are lower than smaller-solute interstitial space distributions due to size restriction.25 Therefore, low control myocardial angiotensinogen is probably the result of ongoing myocardial renin enzymatic depletion of angiotensinogen and also because the available volume of distribution for angiotensinogen within the myocardial extracellular matrix may be similar to albumin.
Alternatively, low control myocardial angiotensinogen levels relative to plasma may have resulted from artificially low determinations of myocardial angiotensinogen. During the 3 minutes' time for removal and cleaning of the myocardium and subsequent homogenization, it is possible that some myocardial angiotensinogen was enzymatically destroyed by renin. However, in vitro incubations simulating control in vivo renin and angiotensinogen concentrations yielded only a negligible fall of myocardial angiotensinogen in 3 minutes. Assay error also appears unlikely, because assay conditions for plasma and myocardium were nearly identical, facilitating comparisons between the two compartments. In addition, the preassay dilution of plasma and ventricular homogenates with PIB containing extensive serine-, metallo-, and thiol-protease inhibitors prevented short-term Ang I breakdown, as demonstrated by a rapidly developed and sustained plateau of generated Ang I and by Ang I spiking of samples. Also, demonstration of a large renin excess for rapid conversion of angiotensinogen to Ang I, excellent blanks, small percent differences between the Ang I concentration at 20- and 40-minute time points, and the fact that when plasma angiotensinogen increases and myocardial renin falls, the measured cardiac angiotensinogen increases as predicted do not make assay artifact seem likely.
Plasma angiotensinogen results in this study are in good agreement with previous determinations.26 However, Danser et al3 reported that angiotensinogen concentrations in pig cardiac tissue were 10% to 25% of those in plasma, versus 2.7±0.25% in the present study. Although the methodology of angiotensinogen assay in the two studies was similar, we briefly perfused hearts with ice-cold saline and thus do not have plasma angiotensinogen contamination, which could have resulted in relatively elevated myocardial angiotensinogen determinations. Significant loss of myocardial angiotensinogen to the perfusate also seems unlikely, since Lindpaintner et al4 showed that significant amounts of angiotensinogen do not leave perfused hearts until well over 20 minutes of constant perfusion.
In the rat, circulating active renin is composed of five major glycoforms (I through V), each with similar enzyme specific activities. The chronic low-salt diet used in this study probably did not alter the proportions of circulating or myocardial control rat renin glycoforms, since very similar renin glycoform proportions were found in a separate group of four normal-salt animals. In addition, a previous study found that chronic high-salt rats and chronic low-salt rats secrete similar renin form proportions from corresponding in vitro kidney slices.27 Since only acute changes in renin secretion stimuli have been previously shown to cause renin glycoform proportional changes,9 12 13 28 it seems unlikely that there are major differences between chronic normal-salt and the low-salt renin glycoform proportions in plasma or myocardium.
In this study, plasma renin and myocardial renin in control rats were found to be composed of the same glycoforms in similar proportions, indicating that all major forms of active renin, regardless of charge or oligosaccharide content, are present in the myocardium. However, high-mannose renin glycoforms possessing relatively small net negative charge (renin glycoforms I and II), are preferentially retained by the myocardium after BNX. At 6 hours BNX, when the concentration and proportion of the high-mannose renin glycoforms I and II were significantly decreased in plasma due to preferential hepatic degradation via the action of the hepatic mannose receptor8 9 10 11 13 and myocardial renin was also decreased, the proportion of renin glycoforms I and II was significantly increased in the myocardium. Measurement of renin glycoforms in the myocardium at 48 hours BNX could not be made due to the overall low level of myocardial renin. Preferential retention of renin glycoforms I and II suggests that myocardial wall exit of (and presumably access to) active renin is a function of net charge and/or oligosaccharide attachments to renin. Thus, myocardial renin derived from plasma renin is unlikely to reflect rapid acute changes in plasma renin for two reasons. First, proportional changes in myocardial renin were always less than plasma renin, indicating that the permeability of the myocardial capillaries to renin was sufficiently low to retard diffusional movement between the plasma and myocardial interstitium. Second, only renin glycoforms I and II participate in acute renin changes in plasma renin concentration,9 12 13 28 yet these same renin glycoforms were preferentially retained by the myocardium after BNX and therefore appear to possess the lowest permeability across the myocardial circulation.
These results are qualitatively similar to a previous study that examined renin glycoform exit from the rabbit carotid artery after BNX.14 In that study, renin glycoforms I and II were also shown to be preferentially retained by the vascular wall. However, the distribution of renin within the carotid wall and the rate of renin exit were both markedly less in the carotid wall than in the myocardium. The role of plasma renin uptake in cardiac interstitial biochemical processes obviously remains obscure. However, these data clarify the active interchange of renin from the kidney to the heart, where sustained local renin activity could subserve chronic functional roles.29
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received June 27, 1996; first decision August 21, 1996; accepted January 29, 1997.
| References |
|---|
|
|
|---|
2.
von Lutterotti N, Catanzaro DF, Sealey JE, Laragh
JH. Renin is not synthesized by cardiac and extrarenal vascular
tissues. Circulation. 1994;89:458-470.
3.
Danser AHJ, van Kats JP, Admiraal PJJ, Derkz FHM,
Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac
renin and angiotensins: uptake from plasma versus in situ
synthesis. Hypertension. 1994;24:37-48.
4.
Lindpaintner K, Jin M, Niedermaier N, Wilhelm MJ,
Ganten D. Cardiac angiotensinogen and its local
activation in the isolated perfused beating heart. Circ
Res. 1990;67:564-573.
5.
Gavras H. Angiotensin-converting
enzyme inhibition and the heart. Hypertension. 1994;23:813-818.
6.
Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict
CR, Pitt B. Emerging role of angiotensin-converting
enzyme inhibitors in cardiac and vascular
protection. Circulation. 1994;90:2056-2069.
7. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.[Abstract]
8.
Katz SA, Opsahl JA, Abraham PA, Gardner MJ. The
relationship between renin isoelectric forms and renin
glycoforms. Am J Physiol. 1994;267:R244-R252.
9.
Abraham PA, Katz SA, Opsahl JA, Miller R, Stanchfield
W, Andersen RC. Renal secretion and hepatic clearance of human
multiple renin forms. Hypertension. 1990;16:669-676.
10.
Sessler FM, Jacquez JA, Malvin RL. Different
production and decay rates of six renin forms isolated from rat
plasma. Am J Physiol. 1986;250:E551-E557.
11. Shier DN, Malvin RL. Differential secretion and removal of multiple renin forms. Am J Physiol. 1985;249:R79-R84.
12. Opsahl JA, Abraham PA, Shake JG, Katz SA. Role of renin isoelectric heterogeneity in renal storage and secretion of renin. J Am Soc Nephrol. 1993;4:1054-1063.[Abstract]
13. Katz SA, Opsahl JA. Biochemistry and physiology of multiple renin forms. In: Laragh JH, Brenner BM, eds. Hypertension. New York, NY: Raven Press; 1994:1489-1502.
14.
Katz SA, Opsahl JA, Forbis LM, Ayenew W. Active
renin and renin glycoform dynamics in the carotid artery.
Am J Physiol. 1996;271:H184-H191.
15. Opsahl JA, Abraham PA, Katz SA. Effect of acute stimulation of renin secretion on renal renin content in vivo. Kidney Int. 1990;38:440-446.[Medline] [Order article via Infotrieve]
16. Katz SA, Abraham PA, Opsahl JA. Measurement of human active renin heterogeneity. Renal Physiol Biochem. 1992;15:240-248.[Medline] [Order article via Infotrieve]
17. Plank B, Raberger G, Brugger G, Adler-Kastner L. The determination of the myocardial extracellular space in the cat in vivo: a comparative methodological study. Basic Res Cardiol. 1976;71:173-178.[Medline] [Order article via Infotrieve]
18. Polimeni PI, Cutilletta AF, Otten MD. Cation distributions in the hypertrophic myocardium (aortic constriction) of the rat. Cardiovasc Res. 1983;17:170-176.[Medline] [Order article via Infotrieve]
19.
Reil GH, Frombach R, Kownatzki R, Quante W, Licthlen
PR. Ascorbic acid: a nonradioactive extracellular space marker
in canine heart. Am J Physiol. 1987;253:H1305-H1314.
20.
Lindpaintner K, Ganten D. The cardiac
renin-angiotensin system: an appraisal of present
experimental and clinical evidence. Circ Res. 1991;68:905-921.
21.
Boer PH, Ruzicka M, Lear W, Harmsen E, Rosenthal J,
Leenen FHH. Stretch-mediated activation of cardiac renin
gene. Am J Physiol. 1994;267:H1630-H1636.
22.
Fordis CM, Megorden JS, Ropchak TG, Kesier HR.
Absence of renin-like activity in rat aorta and microvessels.
Hypertension. 1983;5:635-641.
23.
Schwieler JH, Nussberger J, Kahan T, Hjemdahl P.
Angiotensin II overflow from canine skeletal muscle in
vivo: importance of plasma angiotensin I.
Am J Physiol. 1994;266:R1664-R1669.
24. Figueiredo AFS, Takii Y, Tsuji H, Kato K, Inagami T. Rat kidney renin and cathepsin D: purification and comparison of properties. Biochemistry. 1983;22:5476-5481.[Medline] [Order article via Infotrieve]
25. Kwong MS, Egan EA. Validation of [57Co]cyanocobalamin as an extracellular fluid marker and measurement of albumin exclusion from the interstitium in the rabbit. Microvasc Res. 1985;29:152-160.[Medline] [Order article via Infotrieve]
26. Menard J, Clauser E, Bouhnik J, Corvol P. Angiotensinogen: biochemistry. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. London, UK: Grover Medical Publishers; 1993:8.1-8.10.
27. Katz SA, Malvin RL. Changes in salt intake alter the release of multiple renin species in a nonuniform manner. Ren Physiol. 1984;7:275-282.[Medline] [Order article via Infotrieve]
28. Opsahl JA, Goldberg MR, Katz SA. Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms. Am J Hypertens. 1995;8:1090-1098.[Medline] [Order article via Infotrieve]
29.
Everett AD, Tufro-McReddie A, Fisher A, Gomez
RA. Angiotensin receptor regulates cardiac
hypertrophy and transforming growth factor-ß1
expression. Hypertension. 1994;23:587-592.
This article has been cited by other articles:
![]() |
J. D. Fowler, N. D. Johnson, T. A. Haroldson, J. A. Brintnall, J. E. Herrera, S. A. Katz, and D. A. Bernlohr Regulated renin release from 3T3-L1 adipocytes Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1383 - E1391. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Klotz, D. Burkhoff, I. M. Garrelds, F. Boomsma, and A.H.J. Danser The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur. Heart J., April 1, 2009; 30(7): 805 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Fowler, S. B. Krueth, D. A. Bernlohr, and S. A. Katz Renin dynamics in adipose tissue: adipose tissue control of local renin concentrations Am J Physiol Endocrinol Metab, February 1, 2009; 296(2): E343 - E350. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, N. A. Noble, W. A. Border, R. T. Owens, and Y. Huang Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E810 - E819. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C De Mello Intracellular and extracellular renin have opposite effects on the regulation of heart cell volume. Implications for myocardial ischaemia Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 112 - 118. [Abstract] [PDF] |
||||
![]() |
W. C. De Mello On the Pathophysiological Implications of an Intracellular Renin Receptor Circ. Res., December 8, 2006; 99(12): 1285 - 1286. [Full Text] [PDF] |
||||
![]() |
A.H. J. Danser and J. Deinum Renin, Prorenin and the Putative (Pro)renin Receptor Hypertension, November 1, 2005; 46(5): 1069 - 1076. [Full Text] [PDF] |
||||
![]() |
A. J. Danser and J. Deinum Spotlight on Renin: Renin, Prorenin and the Putative (Pro)renin Receptor Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 163 - 165. [PDF] |
||||
![]() |
E. R. Lumbers, A. C. Boyce, G. Joulianos, V. Kumarasamy, E. Barner, J. L. Segar, and J. H. Burrell Effects of cortisol on cardiac myocytes and on expression of cardiac genes in fetal sheep Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2005; 288(3): R567 - R574. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. De Mello and J. Monterrubio Intracellular and Extracellular Angiotensin II Enhance the L-Type Calcium Current in the Failing Heart Hypertension, September 1, 2004; 44(3): 360 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Peters, R. Farrenkopf, S. Clausmeyer, J. Zimmer, S. Kantachuvesiri, M. G.F. Sharp, and J. J. Mullins Functional Significance of Prorenin Internalization in the Rat Heart Circ. Res., May 31, 2002; 90(10): 1135 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Saris, M. M.E.D. van den Eijnden, J. M.J. Lamers, P. R. Saxena, M. A.D.H. Schalekamp, and A.H. J. Danser Prorenin-Induced Myocyte Proliferation: No Role for Intracellular Angiotensin II Hypertension, February 1, 2002; 39(2): 573 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Marttila, N. Hautala, P. Paradis, M. Toth, O. Vuolteenaho, M. Nemer, and H. Ruskoaho GATA4 Mediates Activation of the B-Type Natriuretic Peptide Gene Expression in Response to Hemodynamic Stress Endocrinology, November 1, 2001; 142(11): 4693 - 4700. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Saris, F. H. M. Derkx, R. J. A. De Bruin, D. H. W. Dekkers, J. M. J. Lamers, P. R. Saxena, M. A. D. H. Schalekamp, and A. H. Jan Danser High-affinity prorenin binding to cardiac man-6-P/IGF-II receptors precedes proteolytic activation to renin Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1706 - H1715. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Saris, F. H. M. Derkx, J. M. J. Lamers, P. R. Saxena, M. A. D. H. Schalekamp, and A. H. J. Danser Cardiomyocytes Bind and Activate Native Human Prorenin : Role of Soluble Mannose 6-Phosphate Receptors Hypertension, February 1, 2001; 37(2): 710 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. De Mello and A. H. J. Danser Angiotensin II and the Heart : On the Intracrine Renin-Angiotensin System Hypertension, June 1, 2000; 35(6): 1183 - 1188. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Katz, J. A. Opsahl, S. E. Wernsing, L. M. Forbis, J. Smith, and L. J. Heller Myocardial renin is neither necessary nor sufficient to initiate or maintain ventricular hypertrophy Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2000; 278(3): R578 - R586. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.H.J. Danser, J. J Saris, M. P Schuijt, and J. P van Kats Is there a local renin--angiotensin system in the heart? Cardiovasc Res, November 1, 1999; 44(2): 252 - 265. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A.M van Kesteren, J. J Saris, D. H.W Dekkers, J. M.J Lamers, P. R Saxena, M. A.D.H Schalekamp, and A.H.J. Danser Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II Cardiovasc Res, July 1, 1999; 43(1): 148 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Hirsch, J. A. Opsahl, M. M. Lunzer, and S. A. Katz Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1818 - H1826. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Virdis, L. Ghiadoni, M. Marzilli, E. Orsini, S. Favilla, P. Duranti, S. Taddei, P. Marraccini, and A. Salvetti Adenosine causes the release of active renin and angiotensin II in the coronary circulation of patients with essential hypertension J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1677 - 1684. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Heller, J. A. Opsahl, S. E. Wernsing, R. Saxena, and S. A. Katz Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1998; 274(3): R849 - R856. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |